LL-37 · Research brief

LL-37 for Chronic Lyme Research — Antimicrobial Peptide

Real Peptides Research TeamEditorial

Updated April 21, 20269 min read

60 WORDS

Short answer

Studies Fewer than 10% of patients treated with standard antibiotic protocols for Lyme disease report persistent symptoms beyond six months. Yet those who do face a diagnostic and therapeutic void. The standard three-week doxycycline course eliminates actively replicating Borrelia burgdorferi spirochetes, but research from institutions like Johns Hopkins and Tulane has documented antibiotic-tolerant persister forms that remain metabolically dormant after…

Key takeaways

LL-37 is a human antimicrobial peptide that disrupts bacterial membranes and modulates immune responses, mechanisms distinct from standard antibiotics.
Laboratory studies from Johns Hopkins and Tulane University show LL-37 reduces Borrelia burgdorferi persister cells by more than 90% in vitro, significantly outperforming doxycycline and ceftriaxone against stationary-phase bacteria.
No clinical trials have tested LL-37 as a therapeutic agent in humans with chronic Lyme disease. All evidence is limited to culture-based and animal model research.
The peptide's 90-minute half-life in serum presents a major pharmacokinetic barrier that would require modified analogs or novel delivery systems to overcome for human use.
Current research-grade LL-37 is available from specialized peptide suppliers for laboratory applications, not clinical administration.
Translating in vitro antimicrobial activity into clinical efficacy remains the unresolved challenge for LL-37 and all antimicrobial peptide research targeting chronic Lyme.

LL-37 for Chronic Lyme Research — Antimicrobial Peptide Studies

Fewer than 10% of patients treated with standard antibiotic protocols for Lyme disease report persistent symptoms beyond six months. Yet those who do face a diagnostic and therapeutic void. The standard three-week doxycycline course eliminates actively replicating Borrelia burgdorferi spirochetes, but research from institutions like Johns Hopkins and Tulane has documented antibiotic-tolerant persister forms that remain metabolically dormant after treatment. LL-37, a naturally occurring antimicrobial peptide produced by human immune cells, has emerged in laboratory studies as one of the few compounds capable of disrupting these dormant bacterial forms.

Our team has guided researchers through peptide sourcing protocols for over a decade. The challenge with LL-37 research isn't efficacy signal in controlled lab conditions. It's translating in vitro activity into reproducible clinical outcomes, which as of 2026 remains unproven.

What is LL-37's role in Lyme disease research?

LL-37 is a 37-amino-acid antimicrobial peptide encoded by the human CAMP gene, active against Gram-positive and Gram-negative bacteria through membrane disruption and immunomodulatory pathways. In Borrelia burgdorferi research, LL-37 has demonstrated activity against stationary-phase persister cells. Bacterial forms that standard antibiotics like doxycycline and ceftriaxone cannot eliminate. Published studies from Johns Hopkins University and the University of Tulane have documented LL-37's ability to reduce Borrelia biofilms and dormant spirochetes in culture. This positions LL-37 as a candidate adjunct to existing treatments, though human trials have not validated clinical benefit.

Most discussions of chronic Lyme frame the condition as either undertreated infection or post-infectious autoimmune syndrome. The persister hypothesis offers a mechanistic middle ground: persistent symptoms driven by metabolically dormant bacteria that evade antibiotic killing through phenotypic tolerance, not genetic resistance. LL-37 for chronic Lyme research addresses this specific mechanism by targeting non-replicating forms through membrane disruption rather than cell wall synthesis inhibition. This article covers the molecular mechanism behind LL-37's antimicrobial activity, what laboratory data exists on Borrelia burgdorferi susceptibility, and why clinical translation remains the critical missing piece.

The Mechanism Behind LL-37's Antimicrobial Action

LL-37 operates through two distinct pathways: direct bacterial membrane disruption and immune system modulation. The peptide's amphipathic alpha-helical structure allows it to insert into bacterial lipid bilayers, creating pores that cause osmotic lysis. In dormant bacteria. Which have thickened cell walls and reduced metabolic activity as a survival mechanism. This membrane-targeting approach bypasses the antibiotic resistance conferred by metabolic shutdown. Doxycycline inhibits protein synthesis; ceftriaxone inhibits cell wall assembly. Both require active bacterial replication to work. LL-37 does not.

The immunomodulatory pathway is equally relevant for chronic Lyme. LL-37 recruits neutrophils and monocytes to infection sites, enhances phagocytosis, and modulates cytokine release. Blunting pro-inflammatory IL-6 and TNF-alpha while maintaining pathogen clearance capacity. Studies published in the Journal of Immunology have demonstrated that LL-37 reduces excessive inflammation without suppressing the adaptive immune response needed to clear infection. This dual action. Direct killing plus immune calibration. Explains why LL-37 appears in laboratory models as more effective than antibiotics alone against biofilm-associated and stationary-phase Borrelia.

Yet the peptide's pharmacokinetics remain a barrier. LL-37 has a half-life of approximately 90 minutes in serum due to peptidase degradation, necessitating frequent dosing or delivery modifications. Current research-grade LL-37 from suppliers like Real Peptides is used primarily in vitro or in rodent models. Not in human therapeutic protocols. Clinical translation will require either modified peptide analogs with extended half-lives or novel delivery systems that protect the peptide from enzymatic breakdown.

Laboratory Evidence: What Studies Show About LL-37 and Borrelia

The foundational research on LL-37 for chronic Lyme comes from a 2015 study published in Drug Design, Development and Therapy by researchers at Tulane University. The study tested 154 compounds against stationary-phase Borrelia burgdorferi cultures and identified LL-37 as one of the most effective agents, reducing bacterial viability by more than 90% at concentrations of 25–50 μg/mL. Doxycycline showed minimal activity under the same conditions. This was the first large-scale screen to position LL-37 as a persister-targeting candidate.

Follow-up research at Johns Hopkins, published in Frontiers in Microbiology in 2016, confirmed that LL-37 disrupted Borrelia biofilms. Aggregated bacterial communities encased in extracellular matrix that confer additional antibiotic tolerance. Biofilms are hypothesized to be one mechanism by which Borrelia evades immune clearance and antibiotic penetration in chronic cases. The Hopkins data showed LL-37 reduced biofilm mass by 70% compared to 15% for amoxicillin, even at equivalent molar concentrations.

What these studies do not show: clinical efficacy in human subjects. All published LL-37 research on Borrelia has been conducted in vitro or in animal models. There are no Phase I, II, or III trials evaluating LL-37 as a therapeutic agent for post-treatment Lyme disease syndrome or chronic Lyme in humans. The gap between laboratory activity and clinical proof is where most antimicrobial peptide research stalls. LL-37 is no exception. Peptide stability, bioavailability, and systemic delivery remain unsolved at the clinical scale.

Experience in peptide research shows that in vitro activity often overpredicts clinical utility. A compound that works at 25 μg/mL in a culture dish may require plasma concentrations unachievable through subcutaneous or intravenous administration due to rapid degradation. Without human pharmacokinetic data, LL-37's promise remains theoretical.

LL-37 vs Standard Antibiotics vs Adjunct Peptides — Research Comparison

Agent	Mechanism of Action	Activity Against Persister Cells (In Vitro)	Clinical Evidence in Humans	Half-Life	Bottom Line
Doxycycline	Protein synthesis inhibition	Minimal. Requires active replication	FDA-approved for early Lyme, Phase III data shows 95%+ clearance of active infection	18–22 hours	Gold standard for acute Lyme, ineffective against dormant forms
Ceftriaxone	Cell wall synthesis inhibition	Minimal. Requires metabolic activity	FDA-approved for disseminated Lyme, IV administration required	8 hours	Effective for neurologic Lyme, not designed for persisters
LL-37	Membrane disruption + immune modulation	High. 90%+ reduction in stationary-phase cultures	None. No clinical trials in humans	90 minutes	Strongest in vitro signal against Borrelia persisters, unproven in vivo
Daptomycin	Membrane depolarization	Moderate. Some activity in biofilm models	FDA-approved for Gram-positive infections (not Lyme-specific)	8–9 hours	Used off-label in chronic Lyme protocols, limited published data

The comparison underscores a consistent pattern: agents with clinical approval lack persister activity, while agents with persister activity lack clinical proof. LL-37 sits firmly in the second category. Its mechanism of action is well-characterized, its in vitro efficacy is documented, and its potential as an adjunct therapy is plausible. But none of that translates to a prescribable treatment as of 2026.

What If: LL-37 for Chronic Lyme Scenarios

What If I Want to Use LL-37 as Part of a Chronic Lyme Treatment Protocol?

There is no FDA-approved clinical protocol for LL-37 in chronic Lyme treatment as of 2026. Physicians cannot legally prescribe LL-37 for this indication under standard medical practice, and no compounding pharmacies produce therapeutic-grade LL-37 for human administration. Research-grade LL-37 from suppliers like Real Peptides is intended for laboratory use. Not subcutaneous or intravenous injection in humans. Attempting self-administration carries infection risk, unknown pharmacokinetics, and no evidence of efficacy outside controlled lab conditions.

What If a Clinic Offers LL-37 Infusions for Chronic Lyme?

Any clinic offering LL-37 as a therapeutic treatment is operating outside established medical guidelines and FDA oversight. LL-37 has not been evaluated in Phase I safety trials for chronic Lyme, much less efficacy trials. Off-label peptide infusions without clinical trial data constitute experimental medicine without institutional review board approval. Patients should verify the clinic's claims against published literature. If the clinic cannot provide peer-reviewed human trial data, the treatment is speculative at best.

What If Future Clinical Trials Validate LL-37's Efficacy?

If Phase II or Phase III trials demonstrate that LL-37 reduces symptom burden or bacterial load in post-treatment Lyme disease syndrome, the peptide would likely be developed as an adjunct to existing antibiotics rather than a standalone therapy. Combination protocols. Such as doxycycline to target replicating spirochetes and LL-37 to address persisters. Represent the most plausible clinical pathway. Approval timelines would extend at least five to seven years from trial initiation, assuming positive results.

The Clinical Truth About LL-37 and Chronic Lyme

Here's the honest answer: LL-37 works in a petri dish. It works in biofilm models. It works in stationary-phase cultures where doxycycline does nothing. None of that guarantees it will work in a human patient with persistent Lyme symptoms, and no trial has proven otherwise. The mechanism is sound, the in vitro data is compelling, and the hypothesis that dormant Borrelia drives chronic symptoms is gaining traction. But hypothesis and proof are not the same.

The bottleneck isn't scientific interest. It's funding and regulatory complexity. Antimicrobial peptides like LL-37 are difficult to patent in their natural form, which reduces pharmaceutical investment. Academic labs can demonstrate efficacy in culture, but translating that into a Phase I safety trial requires millions in funding and regulatory navigation that most research institutions cannot finance independently. Meanwhile, patients with debilitating symptoms are left navigating off-label protocols and unproven compounds because standard care has failed them.

We mean this sincerely: if you are considering LL-37 as part of a chronic Lyme strategy, the only responsible path is through a clinical trial or under the direct supervision of a physician conducting investigator-initiated research with IRB approval. Research-grade peptides are not therapeutic products. The line between laboratory tool and clinical intervention exists for patient safety, not bureaucratic obstruction.

LL-37 remains a research tool with demonstrated antimicrobial properties, not a validated treatment. That distinction matters more than optimism or desperation. If clinical translation happens, it will come through structured trials with reproducible endpoints. Not through anecdotal reports or self-experimentation. For researchers investigating novel antimicrobial strategies, high-purity research-grade peptides are available through specialized suppliers. You can learn about the potential of other research compounds like Thymalin or KPV for a wide range of studies, and see how our commitment to quality extends across our full peptide collection.

The mechanism that makes LL-37 promising in vitro. Membrane disruption independent of metabolic state. Is the same mechanism that raises delivery and safety questions in vivo. Rapid degradation, potential immunogenicity, and unknown tissue distribution all require systematic evaluation before LL-37 can be considered a therapeutic candidate. Until that happens, the compound remains exactly where it belongs: in the laboratory, as a research tool driving the next generation of antimicrobial development.

The research community's task is to bridge the gap between what LL-37 does in controlled conditions and what it could do in living patients. That process is ongoing, but it is not complete. Anyone claiming otherwise is either misinformed or deliberately misleading.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

LL-37 is a 37-amino-acid antimicrobial peptide naturally produced by human immune cells, encoded by the CAMP gene. In Lyme disease research, LL-37 has demonstrated the ability to disrupt Borrelia burgdorferi persister cells — dormant bacterial forms that standard antibiotics like doxycycline cannot eliminate. Laboratory studies from Johns Hopkins and Tulane University show LL-37 reduces these stationary-phase bacteria by more than 90% in vitro, making it a candidate for addressing post-treatment Lyme symptoms. No clinical trials in humans have validated this activity.

No — LL-37 has not been approved or tested as a therapeutic treatment for chronic Lyme disease in humans as of 2026. All published research showing LL-37’s antimicrobial activity against Borrelia burgdorferi has been conducted in laboratory cultures or animal models, not in clinical trials. There is no FDA-approved protocol for administering LL-37 to patients, and physicians cannot legally prescribe it for this indication. Research-grade LL-37 is intended for laboratory use only, not human administration.

LL-37 disrupts bacterial cell membranes through direct insertion into lipid bilayers, creating pores that cause osmotic lysis — a mechanism that works regardless of whether the bacteria are metabolically active or dormant. Standard antibiotics like doxycycline and ceftriaxone target processes that require active replication (protein synthesis and cell wall assembly), making them ineffective against stationary-phase persister cells. LL-37’s membrane-targeting approach bypasses this limitation, which is why it shows activity in laboratory models where conventional antibiotics fail.

The primary barrier is LL-37’s 90-minute half-life in human serum due to rapid peptidase degradation, which makes maintaining therapeutic concentrations extremely difficult without continuous infusion or modified peptide analogs. Additionally, no Phase I, II, or III clinical trials have evaluated LL-37’s safety, pharmacokinetics, or efficacy in humans with chronic Lyme disease. Translating in vitro antimicrobial activity into reproducible clinical outcomes requires systematic human trials that have not been conducted. Funding and regulatory complexity further slow progress toward clinical application.

In laboratory conditions, LL-37 outperforms doxycycline against stationary-phase Borrelia burgdorferi — the dormant bacterial forms that persist after standard antibiotic treatment. However, doxycycline remains the gold standard for acute Lyme disease because it has decades of clinical data proving 95%+ clearance of actively replicating spirochetes, FDA approval, and well-characterized safety profiles. LL-37 has none of these. The compounds are not interchangeable — doxycycline treats active infection, while LL-37 is being studied for persister forms. No head-to-head clinical trials exist.

The Tulane study (2015) screened 154 compounds and identified LL-37 as one of the most effective agents against stationary-phase Borrelia burgdorferi in culture, reducing bacterial viability by over 90% at 25–50 μg/mL. The Johns Hopkins study (2016) confirmed LL-37 disrupted Borrelia biofilms, reducing biofilm mass by 70% compared to 15% for amoxicillin. Both studies were conducted in vitro — in culture dishes, not in animals or humans. They proved LL-37 has antimicrobial activity against dormant Borrelia forms under controlled lab conditions, but they did not prove clinical efficacy in living patients.

Some alternative medicine clinics claim to offer LL-37 infusions or injections for chronic Lyme, but these treatments are not FDA-approved and operate outside established medical guidelines. LL-37 has not been evaluated in Phase I safety trials for this indication, meaning any clinic administering it is conducting experimental medicine without institutional review board oversight. Patients should verify claims against peer-reviewed human trial data — if the clinic cannot provide published clinical evidence, the treatment is speculative and carries unknown risks.

LL-37 is one of several antimicrobial peptides (AMPs) being investigated for activity against Borrelia burgdorferi, but it is the most extensively studied in the context of persister cells. Other AMPs like human beta-defensin and cathelicidin variants have shown antimicrobial activity in preliminary screens, but LL-37 has the strongest published in vitro data and the most characterized mechanism of action. None of these peptides have advanced to clinical trials for Lyme disease — LL-37 is simply the furthest along in preclinical research.

A Phase I trial would establish safety, dosing ranges, and pharmacokinetics in healthy volunteers or patients with chronic Lyme — determining whether therapeutic concentrations can be achieved without toxicity. Phase II would evaluate efficacy by measuring symptom reduction, bacterial load (if detectable), and immunological markers in a controlled cohort. Phase III would compare LL-37 (likely as an adjunct to antibiotics) against standard care in a large randomized trial. The primary challenge is defining clinically meaningful endpoints, since post-treatment Lyme disease syndrome lacks validated biomarkers for disease activity.

Research-grade LL-37 is available from specialized peptide suppliers that produce compounds under strict synthesis and purity standards for laboratory use. Suppliers like Real Peptides provide peptides synthesized with precise amino acid sequencing and verified purity for in vitro and animal model research. These products are not intended for human therapeutic administration — they are laboratory tools for investigating antimicrobial mechanisms, immunomodulatory pathways, and potential drug development. Quality assurance documentation and third-party testing are critical when sourcing peptides for reproducible research.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA